Oliver Giles Best (Giles Best, Oliver G Best, O Giles Best)

ResearcherID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 13

Top Venues

British journal of haematology

International journal of molecular sciences

EJHaem

Physiological reports

Northern Sydney Local Health District

University of Dundee (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Northern Sydney Local Health District Jun 16 2008

Australia

Postdoctoral research fellow :: Kolling Institute

Royal Bournemouth Hospital Dec 01 2003 - Jun 16 2008

United Kingdom

Postdoctoral research scientist :: Molecular Biology

Education History

University of Dundee Jun 01 1999 - Dec 01 2003

United Kingdom

PHD :: Child Health

University of Dundee Oct 01 1995 - Jun 01 1999

United Kingdom

BSC :: Physiology

Publications

Alana M White, Oliver Giles Best, Anya K Hotinski, Bryone J Kuss, Lauren A Thurgood
The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis. Metabolites 13 (7) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
April J Rustia, James S Paterson, Oliver Giles Best, Elke M Sokoya
Microbial disruption in the gut promotes cerebral endothelial dysfunction. Physiological reports 9 (21) (2022)
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P Mulligan
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. EJHaem 3 (1) (2021)
Cuc Do, Oliver Giles Best, Lauren A Thurgood, Anya Hotinski, Sinoula Apostolou, Stephen P Mulligan, Karen Lower, Bryone J Kuss
Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. British journal of haematology 193 (3) (2021)
Narjis Fatima, Yandong Shen, Kyle R Crassini, Edwin J Iwanowicz, Henk Lang, Donald S Karanewsky, Richard I Christopherson, Stephen P Mulligan, Oliver Giles Best
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. EJHaem 2 (1) (2021)
Anya K Hotinski, Oliver Giles Best, Lauren A Thurgood, Karen M Lower, Bryone J Kuss
A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. British journal of haematology 192 (3) (2020)
Kyle R Crassini, William S Stevenson, Stephen P Mulligan, Oliver Giles Best
Molecular pathogenesis of chronic lymphocytic leukaemia. British journal of haematology 186 (5) (2019)
Kyle R Crassini, Yandong Shen, Michael O'Dwyer, Michael O'Neill, Richard Christopherson, Stephen Mulligan, Oliver Giles Best
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British journal of haematology 182 (5) (2018)
Kyle R Crassini, Yandong Shen, William S Stevenson, Richard Christopherson, Chris Ward, Stephen P Mulligan, Oliver Giles Best
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British journal of haematology 182 (3) (2018)

Oliver Giles Best.css-eqlu8i{font-size:small;padding-left:4px;} (Giles Best, Oliver G Best, O Giles Best)

Publication Activity (10 Years)

Top Topics

Top Venues

Oliver Giles Best (Giles Best, Oliver G Best, O Giles Best)